Target Price | $69.20 |
Price | $32.14 |
Potential |
115.31%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target Avidity Biosciences Inc 2026 .
The average Avidity Biosciences Inc target price is $69.20.
This is
115.31%
register free of charge
$96.00
198.69%
register free of charge
$54.00
68.01%
register free of charge
|
|
A rating was issued by 15 analysts: 15 Analysts recommend Avidity Biosciences Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2026 of
115.31%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 10.90 | 6.69 |
14.02% | 38.66% | |
EBITDA Margin | -3,451.01% | -7,808.33% |
41.29% | 126.26% | |
Net Margin | -2,956.88% | -7,603.07% |
33.20% | 157.13% |
13 Analysts have issued a sales forecast Avidity Biosciences Inc 2025 . The average Avidity Biosciences Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2025. The average Avidity Biosciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Avidity Biosciences Inc Analysts have issued a net profit forecast 2025. The average Avidity Biosciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.89 | -4.22 |
0.69% | 46.02% | |
P/E | negative | |
EV/Sales | 373.04 |
6 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Avidity Biosciences Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Raymond James |
Locked
➜
Locked
|
Locked | Jun 11 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Jun 10 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Jun 10 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 12 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | May 09 2025 |
Analyst Rating | Date |
---|---|
Locked
Raymond James:
Locked
➜
Locked
|
Jun 11 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Jun 10 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Jun 10 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Jun 09 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Jun 09 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 12 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
May 09 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.